StreetInsider.com News Articles

Form 4 AbCellera Biologics Inc. For: Feb 27 Filed by: Thermopylae Holdings Ltd.

Mon, 02 Mar 2026 14:17:00 -0500

si-local-file:///var/storage/secattach/20260302/26090954.html

Form 4 AbCellera Biologics Inc. For: Feb 27 Filed by: Thermopylae Holdings Ltd.

Mon, 02 Mar 2026 14:17:00 -0500

si-local-file:///var/storage/secattach/20260302/26090954.html

Form 4 AbCellera Biologics Inc. For: Feb 26 Filed by: Thermopylae Holdings Ltd.

Fri, 27 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260227/26082236.html

Form 4 AbCellera Biologics Inc. For: Feb 26 Filed by: Thermopylae Holdings Ltd.

Fri, 27 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260227/26082236.html

Form 4 AbCellera Biologics Inc. For: Feb 27 Filed by: Booth Andrew

Fri, 27 Feb 2026 14:49:00 -0500

si-local-file:///var/storage/secattach/20260227/26080333.html

Form 4 AbCellera Biologics Inc. For: Feb 27 Filed by: Booth Andrew

Fri, 27 Feb 2026 14:49:00 -0500

si-local-file:///var/storage/secattach/20260227/26080333.html

Form S-8 AbCellera Biologics Inc.

Tue, 24 Feb 2026 16:46:00 -0500

si-local-file:///var/storage/secattach/20260224/26052561.html

Form S-8 AbCellera Biologics Inc.

Tue, 24 Feb 2026 16:46:00 -0500

si-local-file:///var/storage/secattach/20260224/26052561.html

Form 10-K AbCellera Biologics Inc. For: Dec 31

Tue, 24 Feb 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260224/26052402.html

Form 10-K AbCellera Biologics Inc. For: Dec 31

Tue, 24 Feb 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260224/26052402.html

AbCellera (ABCL) Reports FY Loss of $0.49

Tue, 24 Feb 2026 16:15:48 -0500

AbCellera (NASDAQ: ABCL) reported FY EPS of ($0.49). Revenue for the year came in at $75.1 million.

For earnings history and earnings-related data on AbCellera (ABCL) click here.

Form 8-K AbCellera Biologics Inc. For: Feb 24

Tue, 24 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26051746.html

Form 8-K AbCellera Biologics Inc. For: Feb 24

Tue, 24 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26051746.html

AbCellera Reports Full Year 2025 Business Results

Tue, 24 Feb 2026 16:05:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and

AbCellera Reports Full Year 2025 Business Results

Tue, 24 Feb 2026 16:05:00 -0500

AbCellera Reports Full Year 2025 Business Results

Tue, 24 Feb 2026 16:05:00 -0500

AbCellera Reports Full Year 2025 Business Results

Tue, 24 Feb 2026 16:05:00 -0500

Which healthcare stocks are at risk from AI and which to buy

Sat, 14 Feb 2026 10:00:00 -0500

Following the recent selloff in healthcare tech stocks in response to the rollout of new tools/plugins from AI platforms, analysts at KeyBanc Capital Markets consider which names are the most and the least likely to be impacted by AI disruption based on the types of data feeding their platforms.

Companies with more exposure to open-sourced, public data are seen as more at risk, while those with closed-sourced, proprietary and/or more complex datasets to mine are seen as more protected from AI disruption.